1. Home
  2. BZH vs COLL Comparison

BZH vs COLL Comparison

Compare BZH & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BZH
  • COLL
  • Stock Information
  • Founded
  • BZH 1985
  • COLL 2002
  • Country
  • BZH United States
  • COLL United States
  • Employees
  • BZH N/A
  • COLL N/A
  • Industry
  • BZH Homebuilding
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • BZH Consumer Discretionary
  • COLL Health Care
  • Exchange
  • BZH Nasdaq
  • COLL Nasdaq
  • Market Cap
  • BZH 989.6M
  • COLL 1.1B
  • IPO Year
  • BZH 1994
  • COLL 2015
  • Fundamental
  • Price
  • BZH $34.13
  • COLL $29.96
  • Analyst Decision
  • BZH Strong Buy
  • COLL Strong Buy
  • Analyst Count
  • BZH 3
  • COLL 6
  • Target Price
  • BZH $39.67
  • COLL $42.00
  • AVG Volume (30 Days)
  • BZH 364.3K
  • COLL 479.8K
  • Earning Date
  • BZH 11-13-2024
  • COLL 11-07-2024
  • Dividend Yield
  • BZH N/A
  • COLL N/A
  • EPS Growth
  • BZH N/A
  • COLL 757.11
  • EPS
  • BZH 4.53
  • COLL 2.16
  • Revenue
  • BZH $2,330,197,000.00
  • COLL $599,245,000.00
  • Revenue This Year
  • BZH $18.06
  • COLL $13.02
  • Revenue Next Year
  • BZH $7.49
  • COLL $18.01
  • P/E Ratio
  • BZH $7.53
  • COLL $13.85
  • Revenue Growth
  • BZH 5.59
  • COLL 9.62
  • 52 Week Low
  • BZH $25.48
  • COLL $25.16
  • 52 Week High
  • BZH $38.22
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • BZH 58.45
  • COLL 33.15
  • Support Level
  • BZH $32.21
  • COLL $28.97
  • Resistance Level
  • BZH $38.22
  • COLL $30.95
  • Average True Range (ATR)
  • BZH 1.26
  • COLL 1.36
  • MACD
  • BZH 0.12
  • COLL -0.07
  • Stochastic Oscillator
  • BZH 43.90
  • COLL 14.89

About BZH Beazer Homes USA Inc.

Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in over 13 states and over 22 metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the leading sources of revenue for the company. Key metro areas include Atlanta, Las Vegas, Los Angeles, Orlando, and Tampa. The company also focuses on land purchasing and development to support future construction efforts as well as mortgage services for its homebuyers.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: